MRx-4DP0004 Uses, Dosage, Side Effects and more
MRx-4DP0004 is a lyophilised formulation of the Bifidobacterium breve strain of commensal bacteria. It is a live biotherapeutic derived from the microbiota of a healthy human infant.
| Trade Name | MRx-4DP0004 |
| Generic | MRx-4DP0004 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
MRx-4DP0004 is a probiotic bacteria indicated in the treatment of diarrhea.
How MRx-4DP0004 works
MRx-4DP0004 is an immunomodulatory therapy with anti-viral activity that simultaneously downregulates molecules associated with hyper-inflammatory responses. It reduces neutrophilic and eosinophilic infiltration in the lungs, in addition to a reduction in peribronchiolar and perivascular immunopathology without the side effects associated with immunosuppressants. A study of MRx-4DP0004 also demonstrated specifics of the biotherapeutic increasing lung D4+CD44+ cells and CD4+FoxP3+ cells, decreasing activated CD11b+ dendritic cells, and reducing pro-inflammatory cytokines and chemokines involved in neutrophil migration. MRx-4DP0004 is currently being investigated for severe asthma management, however, the specific mechanism of action is currently unknown.
